This project will use advanced methods and techniques as well as new developing molecules for early diagnosis, analysis of recurrence and tailored treatments, to improve long-term response and reduce toxicity in all types of the listed endocrine rare tumors.

The general objective of the project is to improve the clinical management of patients with rare neoplasms such as aggressive hypothalamus-pituitary tumors, adrenal cortical carcinomas, NETs and glioblastomas, through the development of new methods, new technologies, new procedures, new molecules for the initial early diagnosis and recurrence of the disease, for the definition of precise tumor categories with different prognosis, for the prediction of response to more targeted and effective and less toxic therapies, able to be active both on well-differentiated forms with indolent growth and on the more aggressive and poorly differentiated ones.

Funding: POR FESR 2014-2020,

Cost ICAR: 350.000 Euro – Funding ICAR: 280.000 Euro

Duration: 01/01/2019 al 31/12/2021 (data ultima proroga),

Application scope:: Salute

Partners: BioCam S.c.ar.l. Ca.Re.BioS Srl, CNR (IEOS, ICAR), EHealthNet Genomix4Life Srl Laboratorio Cesare Pandolfi & C Sas Materias Srl, Neatec SpA, S.D.N. SpA, SoftLab SpA, Sync Lab S.r.l, Tecnova S.c.ar.l., Università Telematica San Raffaele Università degli Studi di Napoli Federico II, Università degli Studi di Salerno